The decision by Tesco, Musgrave and the BWG Group came after a woman who said Mr McGregor raped her won a civil claim for damages against him. Nikita Hand, who accused the sportsman of raping her in a Dublin hotel in December 2018, won her claim against him for damages in a case at the High Court in the Irish capital. In a statement, a spokesman for Musgrave said: “Musgrave can confirm these products are no longer available to our store network.” The network includes SuperValu, Centra, Daybreak and Mace. A Tesco spokesperson said: “We can confirm that we are removing Proper No Twelve Whiskey from sale in Tesco stores and online.” A spokesperson for BWG Group said: “The products are no longer listed for distribution across our network of Spar, Eurospar, Mace, Londis and XL stores, including Appleby Westward which operates over 300 Spar stores in the south west of England.” It is understood that other retail outlets including Costcutter and Carry Out will also stop stocking products linked to Mr McGregor. He and some of his business partners sold their majority stake in the Proper Number Twelve Irish whiskey brand. He was reported to have been paid more than £103 million from the sale to Proximo Spirits in 2021. On Monday, a popular video game developer decided to pull content featuring the MMA fighter. The Irish athlete has featured in multiple video games, including voice-acting a character bearing his likeness in additional downloadable content in the Hitman series. Mr McGregor’s character featured as a target for the player-controlled assassin in the game. IO Interactive, the Danish developer and publisher of Hitman, said in a statement: “In light of the recent court ruling regarding Conor McGregor, IO Interactive has made the decision to cease its collaboration with the athlete, effective immediately. “We take this matter very seriously and cannot ignore its implications. “Consequently, we will begin removing all content featuring Mr McGregor from our storefronts starting today.” Last Friday, the High Court jury awarded damages amounting to 248,603.60 euros (around £206,000) to Ms Hand. Mr McGregor made no comment as he left court but later posted on social media that he intended to appeal against the decision.Zhengzhou entrepreneurs visit POIC, UMS
CLEVELAND (AP) — Only the Cleveland Browns. Only a team beset by perpetual problems at quarterback for the better part of two decades can get a record-setting 497-yard, four-touchdown, jaw-dropping, where-did-that-come-from performance on Monday night from Jameis Winston — and still lose. History wrapped in misery. Only the Browns. Winston spoiled a high-level performance in Denver's thin air by throwing a pair of pick-sixes — the second with 1:48 remaining — as the Broncos rode big plays to a 41-32 win over the Browns (3-9), who have to wonder what their disappointing season might look like if Deshaun Watson had been benched before getting hurt. The loss ended any illusions the Browns had of making a late playoff push like they did a year ago. It also clinched the team's 22nd losing season since its expansion rebirth in 1999. In his fifth start this season, Winston provided further evidence that the Browns made a major mistake by not switching QBs long before Watson ruptured his Achilles tendon on Oct. 20 against Cincinnati. Cleveland's offense has come alive behind Winston, who has thrown for over 300 yards three times, something Watson didn't do in 19 starts over his three suspension-shortened, injury-riddled seasons with the Browns. While there were some positives, Winston's turnovers were too costly. "You’re not going to play perfect at the quarterback position. He knows that," coach Kevin Stefanski said Tuesday on a Zoom call. “I know that ultimately he wants to do anything in his power to help this team win and that’s going to be taking care of the ball. But he also had moments there where he was moving that offense and did a nice job.” Winston may not be the long-term answer for the Browns, but he's showing he can at least give them a viable option for 2025 while the club sorts through the tangled Watson situation, which continues to have a stranglehold on the franchise. In all likelihood, and assuming he's fully recovered, Watson will be back next season in some capacity with the Browns, who are still on the hook to pay him $92 million — of his fully guaranteed $230 million contract — over the next two seasons. Releasing Watson would have damaging salary-cap implications, and while that would be a bitter financial pill for owners Dee and Jimmy Haslam to swallow, it could the Browns' safest and easiest exit strategy. And if they needed any proof that such a strategy can work, the Browns only had to look across the field at the Broncos, who got out from under QB Russell Wilson's monster contract by cutting him, taking the financial hit and drafting Bo Nix. After some common early growing pains, Nix has settled in and the rookie has the Broncos in the mix for a postseason berth. It wasn't long ago that the Browns thought their quarterback concerns were behind them. Instead, they lie ahead. Stefanski's decision to hand over the play-calling duties to first-year coordinator Ken Dorsey has been a positive. While the move hasn't led directly to many wins, the Browns have moved the ball much more effectively and scored at least 20 points in three of five games since the switch after not scoring 20 in their first eight. An issue all season, Cleveland's defense was again gashed for long plays and TDs, including a 93-yard scoring pass in the third quarter. The Browns have allowed 48 plays of 20-plus yards and 12 of at least 40 yards. WR Jerry Jeudy. His return to Denver was a personal and professional triumph — except on the scoreboard. Vowing revenge on the Broncos, who traded him to the Browns in March, Jeudy had the best game of his career, catching nine passes for 235 yards and a TD. Since Winston took over as Cleveland's starter, Jeudy leads the league with 614 yards receiving. Jeudy just might be the No. 1 receiver the Browns have needed following Amari Cooper's trade. Jordan Hicks gets an honorable mention after recording 12 tackles. K Dustin Hopkins. He missed a 47-yard field goal to end Cleveland's first drive, setting the tone for a night of missed opportunities. After making 33 of 36 field goal tries in his first season with the Browns, Hopkins is just 16 of 23, with his inaccuracy raising questions why the team signed him to a three-year, $15.9 million contract in July. Stefanski had no updates from the game. ... LB Jeremiah Owusu-Koramoah remains sidelined with a neck injury suffered on Nov. 2. Stefanski ruled him out again for Sunday's game at Pittsburgh. 552 — Yards of total offense for the Browns, just 10 shy of the single-game franchise record set in 1989. A short turnaround before visiting the Steelers (9-3), who will be looking to avenge their 24-19 loss in Cleveland on Nov. 21. AP NFL: https://apnews.com/hub/nfl
ROME (AP) — Robert Lewandowski joined Cristiano Ronaldo and Lionel Messi as the only players in Champions League history with 100 or more goals. But Erling Haaland is on a faster pace than anyone by boosting his total to 46 goals at age 24 on Tuesday. Still, Haaland's brace wasn't enough for Manchester City in a 3-3 draw with Feyenoord that extended the Premier League champion's winless streak to six matches. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Texans' Azeez Al-Shaair suspended 3 games without pay after violent hit on Trevor Lawrence HOUSTON (AP) — Houston’s Azeez Al-Shaair was suspended by the NFL without pay for three games for repeated violations of player safety rules following his hit to the head of Jacksonville’s Trevor Lawrence, which led to a concussion. Al-Shaair’s punishment was announced by NFL vice president of football operations Jon Runyan. In his letter to Al-Shaair, he noted that he has had multiple offenses for personal fouls and sportsmanship-related rules violations in recent seasons. Runyan says “video shows you striking the head/neck area of Jaguars’ quarterback Trevor Lawrence after he clearly goes down in a feet-first slide.” Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get any of our free email newsletters — news headlines, obituaries, sports, and more.
How Trump's bet on voters electing him managed to silence some of his legal woesROOKE: Case Of Stripper Vs Privileged College Athletes Still Best Example Of Why The Media Is Broken 18 Years LaterSAN FRANCISCO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 60,000 shares of the Company's common stock, effective as of December 2, 2024. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $10.21 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on December 2, 2024. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan. Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Olema Oncology Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com . Media and Investor Relations Contact Courtney O’Konek Vice President, Corporate Communications Olema Oncology media@olema.com
Ripple's XRP is approaching a critical price point that analysts suggest could trigger a massive rally toward $4. At the same time, market forecasts spotlight DOGEN as a potential game-changer with the possibility of a 50x surge. These bold predictions are stirring excitement, leaving investors eager to see if the markets can deliver on these expectations. DOGEN: The Ultimate Memetoken for Real Alphas Who Always Win Imagine living a dream life — posh cars, fat stacks of cash, and women who turn heads. That’s the DOGEN lifestyle ! If you’re the kind of guy who’s always looking to level up, you need to check out DOGEN. This meme token is for the real alphas who always win . This thing is about to explode! We’re talking about a 700% surge before the presale even wraps up — and that’s just the beginning. DOGEN is heating up to those insane thousand-fold gains that memetokens are famous for this season. Get in early, and watch the others try to keep up while you’re already at the top! ⚡️ Missed Out on WIF, Popcat, or Ponke? ⚡️ DOGEN is the new alpha on the Solana blockchain , running with the big dogs like BONK, WIF, and Popcat — all of which blew up with 1000% gains at some point Right now, DOGEN’s flying under the radar, but it’s about to set new records in this bull run. You don’t want to miss out on this one. Got that DOGEN spirit? Good, ‘cause they’re holding an airdrop ! All you gotta do is flex on social, stack tokens during the presale, and start building your DOGEN army with your referral link. For every recruit, you’ll be snatching a fat 20% of their Golden Points from token buys. So what are you waiting for? Grab some DOGEN and dominate the crypto world! 🚀 XRP: A Digital Currency for Fast and Borderless Transactions XRP is a cryptocurrency created for quick, low-cost, and worldwide payments. It runs on the XRP Ledger, a decentralized system that ensures secure and irreversible transactions without requiring a bank account. Jed McCaleb, Arthur Britto, and David Schwartz designed XRP with an initial supply of 100 billion tokens. Ripple, the organization behind XRP, holds a significant portion and uses it for liquidity and ecosystem support. By operating without central control, XRP aims to simplify currency transfers and enable broader financial access. Its speed and scalability make it stand out in the cryptocurrency market. XRP's performance in the current market depends on broader adoption and technological advancements driving its use case. Conclusion XRP shows moderate short-term potential but remains a key player in the market. DOGEN stands out with its luxury-driven vision, targeting alpha leaders who settle for success. Expected to rise 700% by presale's end, DOGEN mirrors the triumph of tokens like BONK and WIF, offering unmatched growth potential and exclusive perks for early supporters. Site: https://dogen.meme/ Twitter: https://x.com/dogenmeme Telegram: https://t.me/Dogen_Portal Join our WhatsApp Channel to get the latest news, exclusives and videos on WhatsApp _____________ Disclaimer: Analytics Insight does not provide financial advice or guidance. Also note that the cryptocurrencies mentioned/listed on the website could potentially be scams, i.e. designed to induce you to invest financial resources that may be lost forever and not be recoverable once investments are made. You are responsible for conducting your own research (DYOR) before making any investments. Read more here.